An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
This study is for baby boys younger than 9 months who have a serious inherited condition called Ornithine Transcarbamylase (OTC) deficiency. This condition means their body struggles to get rid of a harmful substance called ammonia, which can cause severe health problems. The study is testing a new gene therapy called ECUR-506. Gene therapy aims to fix the faulty gene causing the problem. Researchers want to see if ECUR-506 is safe, how well it works, and what dose is best. It's an early phase study, meaning it's one of the first times this treatment is being tested in people. The hope is to find a new way to help babies with this condition.
במבט חטוף
על מה המחקר הזה?
OTC deficiency is a challenging condition where a baby's body can't process certain waste products properly, leading to a build-up of a toxic substance called ammonia. This build-up can be very dangerous, causing brain damage, coma, and even death if not managed. This condition is inherited and is often more severe in baby boys, appearing shortly after they are born. Current treatments involve special diets and medications, but researchers are always looking for better options.
This study is investigating a new treatment called ECUR-506. It's a type of gene therapy, which means it aims to address the root cause of OTC deficiency – a faulty gene. ECUR-506 works by trying to put a working copy of the missing gene into the liver cells. This working gene would then help the body process ammonia correctly. The therapy is given as a single infusion into a vein.
The main goals of this study are to find out if ECUR-506 is safe for babies, what side effects it might have, and if it helps to improve their condition. It's also looking at different doses to see which one works best. This type of study is an early step in developing new medicines, aiming to gather important information before it can be made widely available.
נקודות עיקריות
- Targets severe OTC deficiency in baby boys.
- Investigates a new gene editing therapy called ECUR-506.
- Aims to replace the faulty gene causing the condition.
- It's an early-stage study focused on safety and dosage.
- A single treatment given by IV infusion.
מי עשוי להיות זכאי?
This study is specifically looking for baby boys who are between 24 hours and 7 months old and weigh between 3.5 kg and 13.5 kg. To join, a baby must have a confirmed diagnosis of severe OTC deficiency, meaning they had a very high ammonia level and symptoms shortly after birth. They should also be receiving the usual treatments for OTC deficiency, like a special diet and medications.
There are also some reasons why a baby might not be able to join. For example, babies who have serious birth injuries affecting their brain, or those needing a liver transplant soon, would not be eligible. If a baby has other serious health problems, such as major organ damage, or has already had gene therapy, they also wouldn't be able to take part. The study also needs parents or guardians who can understand and agree to the study requirements.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- Is your baby a boy?
- Is your baby under 7 months old?
- Does your baby have severe OTC deficiency confirmed by a genetic test?
- Did your baby have very high ammonia levels soon after birth?
- Is your baby currently on a special diet and medication for OTC deficiency?
מה כרוך בהשתתפות?
We don’t have all the details about what participating involves, but generally, studies like this include regular hospital visits for check-ups, blood tests, and other assessments to monitor your baby's health and how the treatment is working. The study drug, ECUR-506, is given once as an infusion into a vein. There will be long-term follow-up to see how your baby is doing after the treatment. The total duration of participation isn't specified here, but gene therapy studies often involve monitoring for several years.
סיכונים ותועלות פוטנציאליים
מיקומים (12)
- UCLA Mattel Children's Hospitalמיקוד מאומתלוס אנג'לס, ארצות הברית
- Children's Hospital of Colorado, Anshutz Medical Campusמיקוד מאומתאורורה, ארצות הברית
- בית הספר לרפואה של אוניברסיטת אמורימיקוד מאומתאטלנטה, ארצות הברית
- בית החולים לילדים אן ורוברט ה. לורי בשיקגומיקוד מאומתשיקגו, ארצות הברית
- Icahn School of Medicine at Mount Sinaiמיקוד מאומתניו יורק, ארצות הברית
- Oregon Health and Science Universityמיקוד מאומתפורטלנד, ארצות הברית
- The Children's Hospital at Westmeadמיקוד מאומתSydney, Australia
- The Royal Children's Hospitalמיקוד מאומתמלבורן, אוסטרליה
- Hopsital Sant Joan de Deuמיקוד מאומתברצלונה, ספרד
- Hospital Universitario 12 de Octubreמיקוד מאומתמדריד, ספרד
- Great Ormond Street Hospitalמיקוד מאומתלונדון, הממלכה המאוחדת
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospitalמיקוד מאומתניוקאסל על הטיין, הממלכה המאוחדת
שאלות נפוצות
What is OTC deficiency?
It's a serious inherited condition where the body can't properly remove a harmful substance called ammonia, which can build up to dangerous levels.
What is gene therapy?
Gene therapy aims to correct genetic problems by introducing a working copy of a faulty gene into the body.
מי יכול להצטרף למחקר זה?
Only baby boys under 7 months old with a severe type of OTC deficiency can be considered for this study.
How is the treatment given?
The gene therapy, ECUR-506, is given as a single treatment through a drip into a vein.
Will my baby still need their usual treatments?
Yes, babies in the study will continue to receive their standard treatments, such as special diets and scavenger medications.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.